Patent ID: 9683264
Date: 2017-06-20
CPC Classifications: A61N,C12Q

Claim:
1. A non-invasive method for the prediction of the onset of metastasis in a primary breast cancer patient or the progression-free survival (PFS) or overall survival (OS) of a patient with metastatic breast cancer, comprising: (a) providing a biological sample from a primary breast cancer patient or a patient with metastatic breast cancer; (b) analyzing the biological sample to determine the amount of at least one miRNA; (c) normalizing the amount of the at least one miRNA to an endogenous control comprising miR-29a and/or miR-139-5p; wherein: an increased level of miR-144, miR-215, miR-486-5p, or any combination thereof is indicative of increased OS of the patient with metastatic breast cancer; a decreased level of miR-141, miR-193b, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-365, miR-375, miR-429, miR-801, miR-1260, miR-1274a, or any combination thereof is indicative of increased OS of the patient with metastatic breast cancer; an increased level of miR-144, miR-215, or a combination thereof is indicative of increased PFS of the patient with metastatic breast cancer; a decreased level of miR-141, miR-193b, miR-200a, miR-200b, miR-200c, miR-203, miR-375, miR-429, miR-1274a, or any combination thereof is indicative of increased PFS of the patient with metastatic breast cancer; an increased level of miR-200a, miR-200b, miR-200c, miR-210, miR-486-5p, or any combination thereof is indicative of an increased risk of the onset of metastasis in the primary breast cancer patient; and/or a decreased level of miR-215 is indicative of an increased risk of the onset of metastasis in the primary breast cancer patient.